Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Eryaspase Plus Chemotherapy vs Chemotherapy Alone in Second-Line Pancreatic Adenocarcinoma
2018-000572-15Phase 3Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Jun 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of eryaspase in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by PHAXIAM Therapeutics. Primary endpoint: Overall survival. Started Jun 2018; status: completed.
02
Drugs
eryaspase
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-000572-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000572-15.